Vision and Mission

SINGAPORE SCIENCES is a pioneering biopharmaceutical leader dedicated to transforming healthcare through research-driven, clinically tested solutions for chronic diseases. With a robust portfolio and cutting-edge pipeline spanning endocrinology, immunology, and oncology, we leverage the most advanced innovations to develop premium therapeutic products.

Our mission is to redefine how diseases like diabetes, immune deficiencies, and cancer are prevented and treated, delivering hope and improved outcomes to patients worldwide.

Built upon a foundation grounded in scientific evidence, 
​SINGAPORE SCIENCES is recognized as the leader in the field of novel healthcare research & product developments. 

Each year SINGAPORE SCIENCES sponsors numerous research projects in leading institutes in Singapore and internationally on cutting edge research, including double-blind, placebo-controlled studies proving the safety and efficacy of its premier products.

Founders' Background

Patrick H.M. Loh

HonDSc, BBM, PBM

Professor Patrick H.M. Loh

HonDSc, BBM, PBM

Singapore Distinguished Professor (Murdoch University, Western Australia)
Chartered Horticulturist (C Hort, UK), Certified Practicing Agriculturalist (CPAg, Australia)
Agri-Adviser, Agri-Food & Veterinary Authority of Singapore (AVA) 2002-2011
Member, Royal Agricultural Society of Western Australia

Co-founder and Chairman

Professor Loh is Co-founder and Chairman of SINGAPORE SCIENCES and SINOAGRO GROUP. A practising plant scientist, Professor Loh is one of the early pioneering bio-entrepreneurs in Singapore who successfully established the commercial application of biological and molecular techniques to plant and crop improvements in the agro-based industries in the ASEAN region.

​Professor Patrick H.M. Loh is Chairman and Co-Founder of SINGAPORE SCIENCES and SINOAGRO GROUP.  Professor Loh’s distinguished and illustrious career spanned more than two decades both in the academic and corporate world, where he is a professor, chairman and advisor in many institutions and organisations.

Mr P.F. Chang

Chartered Engineer, CEng (UK)
Full Member, Institute of Physics and Engineering in Medicine (UK)
Member, Institution of Engineering and Technology (UK)
Bachelor of Engineering in Bioengineering, B.Eng (Singapore)

Co-founder and CEO

Mr Chang holds a Bachelor of Engineering degree with a Major in Bioengineering from Nanyang Technological University (NTU) in Singapore. In 2010, he established his first agrobiotech company to produce and supply biotech-derived therapeutic materials to healthcare corporations in Singapore. In 2012, he developed and secured CPM approval from the Health Sciences Authority (HSA) of Singapore for the first High Active Ingredient Certified-Organic medicinal capsule in Singapore (Grant of intellectual property rights, 2012, IPOS).

​Mr P.F. Chang graduated with a Bachelor of Engineering, Major in Bioengineering from the Nanyang Technological University (NTU) in Singapore. Whilst reading for his Bachelor’s degree, he was one of the few undergraduates selected to join the Bioengineered & Applied Nanomaterials Laboratory in NTU to undertake drug formulation/delivery project pertaining to the investigation of ‘Protein Nanocages’.

DR .Tan Chee Eng

SINGAPORE SCIENCES Medical Specialist Adviser

Consultant Physician & Endocrinologist MBBA, MMed (Int Med) FAMS (S'pore), PhD (Glasgow)

Dr Tan Chee Eng is Consultant Endocrinologist at the renowned Gleneagles Medical Centre in Singapore. Before starting private practice at Gleneagles Medical Centre in 2004, he was the Head of Department of Endocrinology at the Singapore General Hospital (SGH) for 5 years. Whilst at SGH, he was responsible for starting up the first Lipid unit in Singapore and also pioneered the electronic medical record for diabetes mellitus consultation (DMCARE).

SINGAPORE SCIENCES Medical Specialist Adviser

Consultant Physician & Endocrinologist

MBBA, MMed (Int Med)

FAMS (S'pore), PhD (Glasgow)

Medical education

Dr Tan Chee Eng is Consultant Endocrinologist at the renowned Gleneagles Medical Centre in Singapore. Before starting private practice at Gleneagles Medical Centre in 2004, he was the Head of Department of Endocrinology at the Singapore General Hospital (SGH) for 5 years. Whilst at SGH, he was responsible for starting up the first Lipid unit in Singapore and also pioneered the electronic medical record for diabetes mellitus consultation (DMCARE).

Endocrinologist expertise

Dr Tan's medical career began in 1984 when he graduated with the Bachelor of Medicine & Surgery from the National University of Singapore (NUS). Following that, he completed his Masters in Internal Medicine at NUS and PhD at the University of Glasgow, United Kingdom.

Prolific researcher

He is currently a member of the Lipid Guidelines committee, Ministry of Health (MOH), Singapore. He is a founder member and member of the Executive Council for the Asian Pacific Society of Atherosclerosis and Vascular Disease since 1999. He is currently also on the executive committee, Regional Federation for Asia Pacific, International Atherosclerosis Society. He was previously involved in both the Lipid Guidelines and Diabetes guidelines committee of the Ministry of Health (MOH), Singapore. He was also a member of the Singapore Ministry of Health taskforce on obesity. Other past appointment includes Adjunct Associate Professor with the Centre for Molecular Epidemiology, National University of Singapore (NUS).

Consultant endocrinologist

​Dr Tan is a practising endocrinologist and has been managing patients with diabetes mellitus, cholesterol problems and obesity for the past 25 years. Therefore he is a firm believer in the benefits of exercise, nutrition and lifestyle changes in management of chronic metabolic diseases.

He has published more than 90 articles in International peer-reviewed journals and spoken at more than 300 international and local symposiums. He was also on the International Steering committee of a few international collaborative studies on risk factors for heart disease and diabetes mellitus.

Our R&D Initiatives and Collaborators

Advisory Board Members

Our Advisory Board comprises distinguished leaders who provide strategic guidance on the evolving global scientific landscape. They challenge our thinking and help steer our company’s vision, ensuring we remain at the forefront of scientific innovation and market opportunities.

SINGAPORE SCIENCES is a biopharmaceutical company that develops research-based, clinically tested healthcare products that addresses chronic diseases. Our portfolio and pipeline spanning endocrinology (diabetes), immunology and oncology, our goal is to use the most innovative approach in developing therapeutic products of the highest quality, to change the way how diseases such as diabetes, immune deficiencies and cancer are prevented and treated.

Each year SINGAPORE SCIENCES sponsors numerous research projects in leading institutes in Singapore and internationally on cutting edge research, including double-blind, placebo-controlled studies proving the safety and efficacy of its premier products.

Built upon a foundation grounded in scientific evidence, SINGAPORE SCIENCES is recognized as the leader in the field of novel healthcare research & product developments.

Our Research Areas

Lorem ipsum dolor sit amet, consectetur adipiscing elit pellentesque lectus.

Featured Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit pellentesque lectus.

Shop

Lorem ipsum dolor sit amet, consectetur adipiscing elit pellentesque lectus.

Peter Waring

B.Com (Hons), LLB (Hons) Macq GradDip Collaw, PhD Newcastle (NSW) GAICD

Professor Peter Waring is Murdoch University’s Pro Vice Chancellor of Transnational Education and Singapore Dean. Professor Waring is responsible for advancing the University’s academic and strategic interests transnationally. A qualified lawyer, Peter also holds degrees in Commerce and Management and is a graduate of the Australian Institute of Company Directors where he now serves on their National Education Advisory Board. Peter is the co-author of five books and overall has published more than a hundred book chapters and articles in leading international and national journals. His research and teaching interests span the business and law fields of employment relations, human resource management, corporate governance, labour law, Artificial Intelligence and Higher Education Policy. He has lived in Singapore for the last 24 years.

Lawrence Y.K. Loh

B.B.A (Hons), PhD Massachusetts Institute of Technology (USA)

Professor Lawrence Loh is Director, Centre for Governance and Sustainability (CGS) at NUS Business School, National University of Singapore. At CGS, Lawrence leads the new Singapore Governance and Transparency Index project in collaboration with CPA Australia, Singapore Institute of Directors and The Business Times. He also heads the ASEAN Corporate Governance Scorecard project conducted together with the Singapore Institute of Directors. Lawrence oversees the joint Business Integrity and Sustainability Reporting initiatives with the ASEAN CSR Network as well as the study on sustainable finance with WWF. Lawrence received a PhD in Management from Massachusetts Institute of Technology. He had served in key leadership positions in universities and alliances across Asia Pacific and Middle East. Lawrence has been appointed in government committees and think-tanks in education, information communications, and science and technology. He was lead consultant on information and technology policy studies for various government agencies. Lawrence also consulted for Fortune 500 companies and international organisations in the areas of quality management and technology strategy. Lawrence has published in international journals including Management Science, Information Systems Research and Journal of Management Information Systems, and has co-authored a book entitled "The Quest for Global Quality: A Manifestation of Total Quality Management by Singapore Airlines" published by Addison-Wesley. Lawrence is a regular commentator on corporate governance and sustainability for the global and Singapore media, such as BBC, Bloomberg, CNN, The Washington Post, The Business Times, The Straits Times and Channel NewsAsia. At NUS, Professor Lawrence teaches strategic management and corporate governance for undergraduate, graduate and executive programs.

Chia Hock Lai

B.Sc (Hons), National University of Singapore (NUS)

Mr Chia Hock Lai is a prominent and accomplished fintech leader and recognized ecosystem builder with nearly two decades of experience across public and private sectors. He is widely known as a co-founder of pivotal industry organizations including the Singapore FinTech Association (SFA), Blockchain Association Singapore (BAS), and Digital Assets Association (DAA). He currently serving as Co-founder and Asia CEO of Embed Financial Group Holdings, he drives strategic growth for fintech services across Asia and Africa. His advisory roles include guiding the Brunei Darussalam Central Bank on national fintech policy and supporting market expansion for international payments fintech ibanera LLC. Previously, he led digital transformation at NTUC Income and shaped e-Government initiatives at GovTech Singapore. Mr Chia continues to influence the global fintech landscape as Chairman of the Responsible Fintech Institute (RFI) and Co-founder of the International Digital Economies Association (IDEA). His contributions have been honored with the IBF Fellowship for Digital Transformation and the SkillsFuture Fellowship. He has completed an executive education at the Massachusetts Institute of Technology (MIT), USA.